Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Open Access
- 1 April 2014
- journal article
- review article
- Published by Taylor & Francis Ltd in Biologics: Targets and Therapy
- Vol. 8, 129-39
- https://doi.org/10.2147/btt.s39381
Abstract
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Neda Stjepanovic, Jaume CapdevilaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumorigenesis of thyroid cancers has led to development of new targeted agents for the management of advanced and refractory disease. Multikinase inhibitors that are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer have been the most widely studied. After an international effort to identify and recruit sufficient patients, four placebo-controlled studies of multikinase inhibitors have been completed. These trials have led to the approval of the first agents with activity in advanced medullary thyroid cancers, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future. The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.Keywords: thyroid cancer, lenvatinib, tyrosine kinase inhibitors, multikinase inhibitors, targeted therapiesKeywords
This publication has 50 references indexed in Scilit:
- Cabozantinib in Progressive Medullary Thyroid CancerJournal of Clinical Oncology, 2013
- Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk FactorsJournal of Cancer Epidemiology, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Cytotoxic Chemotherapy for Differentiated Thyroid CarcinomaClinical Oncology, 2010
- Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005Cancer, 2009
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles forBRAF, PIK3CA, andAKT1Cancer Research, 2009
- Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosisExpert Review of Molecular Diagnostics, 2008
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006
- Survival and Death Causes in Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2006
- Regulation and targets of receptor tyrosine kinasesEuropean Journal of Cancer, 2002